Trial NC-HEM-14-6


Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 (Anti-CD40L dAb) in Adult Subjects with Primary Immune Thrombocytopenia (ITP)

Type: Treatment
Phase:
Status: Not Open (Closed)
Treatments:
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Howard Liebman, M.D.
Other Trial Staff:  Christine Duran, Coordinator, Christine Duran, D.M., Melissa Peralta, D.M., Teresa Olea, R.N., Donna Fernando, Coordinator, Meena Ibrahim, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.